Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Y Sanchez Gonzalez"'
Autor:
G D'Haens, J Tran, S Danese, D T Rubin, N Aoyama, A Lügering, J Klaff, S Xuan, D Ilo, Y Sanchez Gonzalez, J Panes
Publikováno v:
Journal of Crohn's and Colitis. 17:i27-i29
Background Abdominal pain (AP), bowel urgency (BU), stool frequency (SF), rectal bleeding (RB) and fatigue are debilitating symptoms that reduce quality of life in patients with ulcerative colitis (UC). Results from two Phase 3 induction trials and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26ea7a0f84780ca2fea3ae29f95e9d30
https://doi.org/10.1093/ecco-jcc/jjac190.0020
https://doi.org/10.1093/ecco-jcc/jjac190.0020
Autor:
K V Patel, P Salmon, I Marin-Jiménez, M Thessen, K Kligys, D Sharma, Y Sanchez Gonzalez, J Kershaw
Publikováno v:
Journal of Crohn's and Colitis. 17:i544-i546
Background Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) with increasing healthcare resource utilisation (HCRU) and associated costs. Optimal management of CD and UC aims to induce and maintain remis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9787fd56d5e5b1fcdaf469e6ba196e39
https://doi.org/10.1093/ecco-jcc/jjac190.0546
https://doi.org/10.1093/ecco-jcc/jjac190.0546
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R Panaccione, E B Collins, G Y Melmed, S Vermeire, S Danese, P D R Higgins, W Zhou, D Ilo, D Sharma, Y Sanchez Gonzalez, S T Wang
Publikováno v:
Journal of Crohn's and Colitis. 16:i037-i041
Background The therapeutic armamentarium to treat adult patients with moderately to severely active ulcerative colitis (UC) continues to evolve. With this rapid innovation, the comparative efficacy and safety of more recent advanced therapies remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eda110baec24c7872aba18d88394db97
https://doi.org/10.1093/ecco-jcc/jjab232.033
https://doi.org/10.1093/ecco-jcc/jjab232.033
Autor:
W Reinisch, J Tran, K Patel, N Borruel, G Y Melmed, L Wegrzyn, G Levy, D Ilo, Y Sanchez Gonzalez, R Panaccione
Publikováno v:
Journal of Crohn's and Colitis. 17:i785-i786
Background Upadacitinib (UPA) and tofacitinib (TOFA) are Janus kinase (JAK) inhibitors approved for the treatment of patients (pts) with moderately to severely active ulcerative colitis (UC), but evidence on their comparative efficacy and safety is l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ae3cf04d1a0209d70c7f92cae64d7cd
https://doi.org/10.1093/ecco-jcc/jjac190.0788
https://doi.org/10.1093/ecco-jcc/jjac190.0788
Autor:
I Blumenstein, S Xuan, R Panaccione, F Baert, M Barreiro-de Acosta, B D Ye, J Klaff, R Vladea, G Levy, C T J Holweg, Y Sanchez Gonzalez, M C Dubinsky
Publikováno v:
Journal of Crohn's and Colitis. 17:i333-i334
Background Upadacitinib (UPA) demonstrated efficacy and safety as induction and maintenance therapy for ulcerative colitis (UC) in Phase 3 trials U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026). This post-hoc analysis aims to characterise the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3687a83b9835d7eebd3c1ed419864e88
https://doi.org/10.1093/ecco-jcc/jjac190.0309
https://doi.org/10.1093/ecco-jcc/jjac190.0309
Autor:
W Reinisch, R Panaccione, M Duijvestein, D Ceballos Santos, G Y Melmed, S Xuan, L Wegrzyn, G Levy, D Ilo, Y Sanchez Gonzalez
Publikováno v:
Journal of Crohn's and Colitis. 17:i672-i673
Background Upadacitinib (UPA), an oral Janus kinase inhibitor, and ustekinumab (UST), a parenteral IL-12/23 inhibitor, are approved therapies for patients (pts) with moderately to severely active Ulcerative Colitis (UC). In the absence of head-to-hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d21830a14a831c3ea0805788ddbadb0a
https://doi.org/10.1093/ecco-jcc/jjac190.0676
https://doi.org/10.1093/ecco-jcc/jjac190.0676
Autor:
Wen Zhou, M A Weinreich, Silvio Danese, Severine Vermeire, Aileen L. Pangan, Hiroshi Nakase, R Pannaccione, Peter D.R. Higgins, Bidan Huang, Xavier Hébuterne, Y Sanchez-Gonzalez, M H Chen, Wangang Xie, Jesse S. Siffledeen, J Liu
Publikováno v:
Journal of Crohn's & Colitis
Background An unmet therapeutic need remains in patients with ulcerative colitis (UC). U-ACHIEVE is one of two phase 3 induction trials evaluating the safety and efficacy of the selective Janus kinase–1 inhibitor upadacitinib (UPA) 45 mg once daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d1e313c4b142af5c947df4d3a77994b
https://doi.org/10.1093/ecco-jcc/jjab075.023
https://doi.org/10.1093/ecco-jcc/jjab075.023
Autor:
R Panaccione, S Danese, W Zhouwen, A Pangan, X Hébuterne, H Nakase, G D’Haens, J Panes, J Lindsay, P Higgins, E Loftus, W Sandborn, W Xie, Y Sanchez gonzalez, J Liu, M Weinreich, S Vermeire
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 5:18-19
Background Upadacitinib (UPA), an oral selective and reversible JAK inhibitor, demonstrated significantly greater efficacy compared with placebo (PBO) for induction of remission in patients with moderately to severely active ulcerative colitis (UC) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd739a45ec159953cde100adeee46274
https://doi.org/10.1093/jcag/gwab049.144
https://doi.org/10.1093/jcag/gwab049.144